Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
Rifampicin; Isoniazid
Sanofi-Aventis Ireland Limited T/A SANOFI
J04AM; J04AM02
Rifampicin; Isoniazid
150 mg/100 milligram(s)
Film-coated tablet
Product subject to prescription which may not be renewed (A)
Combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid
Marketed
1977-04-01
Internal RIFINAH® 150/100MG FILM-COATED TABLETS _Rifampicin 150mg _ _Isoniazid 100mg _ IS THIS LEAFLET HARD TO SEE OR READ? PHONE 01 403 5600 FOR HELP. Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Rifinah is and what it is used for 2. What you need to know before you take Rifinah 3. How to take Rifinah 4. Possible side effects 5. How to store Rifinah 6. Contents of the pack and other information 1. WHAT RIFINAH IS AND WHAT IT IS USED FOR Rifinah 150/100mg Film-Coated Tablets are used to treat tuberculosis (also known as TB) of the lung and certain other mycobacterial infections. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE RIFINAH Do not take Rifinah if: - You are allergic (hypersensitive) to the active ingredients (isoniazid or rifampicin) or to any of the other ingredients. - You have yellowing of the skin and eyes (jaundice). - You are taking saquinavir or ritonavir for HIV infection (see ‘Taking other medicines’ section below). Do not take if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Rifinah. Internal WARNINGS AND PRECAUTIONS INFORM YOUR DOCTOR IMMEDIATELY WHILE TAKING THIS MEDICINE IF: • Your symptoms of tuberculosis return or get worse (see 4. Possible side effects) • if you develop new or sudden worsening of shortness of breath, possibly with a dry cough or fever not responding to antibiotic treatment. These could be symptoms of lung inflammation (interstitial lung disease/pneumonitis) and can lead to serious breathing problems due to collection of fluid in the lungs and interfere with normal breathing wh Preberite celoten dokument
Health Products Regulatory Authority 14 March 2024 CRN00DR74 Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rifinah 150/100 mg Film- Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150mg Rifampicin and 100mg Isoniazid. Excipients: Sucrose 110.06mg Sodium 0.9mg. For a full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM Film-coated tablets (tablets). Cyclamen, smooth, shiny, round, curved sugar-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of tuberculosis, and other mycobacterial infections. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Rifinah should be given at least 30 minutes before a meal or 2 hours after a meal. _Adults Only: _Rifampicin 450-600mg (10mg/kg b.w) daily as a single dose combined with Isoniazid 5mg/kg b.w. _Use in the elderly:_ Caution should be exercised in using rifampicin in such patients especially if there is evidence of liver function impairment. _Use in impaired liver function: _A daily dose of 8mg/kg/day should not be exceeded in patients with impaired liver function. Concomitant administration of pyridoxine (B6) is recommended in the elderly, malnourished, in those predisposed to neuropathy (e.g. diabetics) and in adolescents. 4.3 CONTRAINDICATIONS Use in patients with jaundice. Use in patients with known hypersensitivity to the rifamycins, isoniazid or any of the components. Rifinah use is contra-indicated when given concurrently with the combination of saquinavir/ritonavir _(see section 4.5)_ Administration at the same time as some formulations of para-aminosalicylic acid, since such a combination will not permit adequate blood levels of either. Dosage of each should be separated by at least eight hours, unless the formulation of PAS has been shown not to inhibit absorption. Use in patients with manic or hypomanic psychoses. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Health Products Regulatory Authority 14 March 2024 CRN00DR74 Page 2 of 13 Rifinah is a combination of two drugs, each Preberite celoten dokument